Imigran

Sumatriptan, the active ingredient in Imigran, is a selective serotonin (5‑HT1) receptor agonist presented as a 6 mg/0.5 mL injection solution for subcutaneous use. It treats acute migraine attacks with or without aura and is also used for acute cluster headache in some regions.

GNH USA supplies Imigran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU GMP standards and provides secure, timely regulatory logistics for bulk and unit‑dose shipments efficiently.

Sumatriptan is indicated for acute treatment of migraine and related headache disorders. - Migraine with aura: rapid relief of headache and associated symptoms during an acute attack. - Migraine without aura: rapid relief of headache and associated symptoms during an acute attack. - Cluster headache (off‑label in some regions): may shorten the duration and lessen severity of an acute cluster episode.

Common Side Effects: - Injection site pain: mild discomfort at the subcutaneous injection site. - Tingling or numbness: transient paresthesia in the face or extremities. - Flushing: temporary reddening of the skin. - Nausea: mild upset stomach.

Serious or Rare Side Effects: - Chest discomfort or tightness: may indicate cardiac ischemia and requires immediate evaluation. - Severe hypertension: sudden rise in blood pressure that can be dangerous. - Serotonin syndrome: rare but potentially life‑threatening condition when combined with other serotonergic agents. - Allergic reaction: includes rash, swelling, or anaphylaxis.

Before using Imigran, consider the following precautions: - Cardiovascular disease: avoid in patients with coronary artery disease, uncontrolled hypertension, or history of myocardial infarction. - Cerebrovascular disorders: contraindicated in patients with stroke or transient ischemic attack history. - Hemiplegic or basilar migraine: not recommended due to risk of vasoconstriction. - Concomitant serotonergic drugs: monitor for serotonin syndrome when used with SSRIs, SNRIs, MAO inhibitors, or other triptans. - Pregnancy and lactation: safety not established; use only if potential benefit justifies risk. - Store at ambient temperature: keep below 25 °C, protect from moisture and light, retain in original packaging.

Sumatriptan may interact with several drug classes. Major Interactions (Avoid): - MAO inhibitors: risk of severe hypertension and serotonin syndrome. - Ergot alkaloids: additive vasoconstriction may cause serious cardiovascular events. - Other triptans: combined use can increase risk of vasospasm and serotonin toxicity. Moderate Interactions (Monitor Closely): - SSRIs, SNRIs, TCAs: may increase serotonin levels, monitor for serotonin syndrome. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): can raise sumatriptan plasma concentrations. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy of sumatriptan.